Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genvec Inc (GNVC)

Genvec Inc (GNVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genvec Inc 910 CLOPPER ROAD SUITE 220N GAITHERSBURG MD 20878 USA

www.genvec.com P: 240-632-0740

Description:

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade is currently in a pivotal Phase II/III study in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and metastatic melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease.

Key Statistics

Overview:

Market Capitalization, $K 16,321
Shares Outstanding, K 2,270
Annual Sales, $ 510 K
Annual Net Income, $ -5,790 K
Last Quarter Sales, $ 110 K
Last Quarter Net Income, $ -4,270 K
60-Month Beta 3.34
% of Insider Shareholders 8.10%
% of Institutional Shareholders 6.22%

Growth:

1-Year Return 19.83%
3-Year Return -71.91%
5-Year Return -69.66%
5-Year Revenue Growth -97.13%
5-Year Earnings Growth -52.07%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 08/04/17
Earnings Per Share ttm -3.65
EPS Growth vs. Prev Qtr -180.60%
EPS Growth vs. Prev Year -70.91%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 12/01/16

GNVC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -178.26%
Return-on-Assets % -101.30%
Profit Margin % -1,135.29%
Debt/Equity 0.00
Price/Sales 32.08
Price/Cash Flow N/A
Price/Book 28.20
Book Value/Share 0.26
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar